SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 27, 2018--
Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced publication of the preclinical
results of its oral F-protein based Respiratory Syncytial Virus (RSV-F)
vaccine. The findings were published in the most recent online version
of Vaccine (Joyce C. et al., “Orally administered
adenoviral-based vaccine induces respiratory mucosal memory and
protection against RSV infection in cotton rats”).
As described in the article, the oral RSV-F vaccine candidate provided
complete sterilizing protection against RSV infection in the cotton rat
challenge model at the target dose. The vaccine induced significant and
dose-dependent neutralizing antibody responses in serum, as well as
multi-functional effector and memory B cell responses at the mucosal
surface along the respiratory tract. Importantly, the Vaxart oral RSV-F
vaccine did not cause any inflammatory pathology in the respiratory
tract.
“Based on these results, we believe that our proprietary platform is
uniquely suited as the optimal delivery system for an RSV vaccine,” said
Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart. “We
were particularly pleased with the strong mucosal immune responses that
were generated in the respiratory tract. Those trended higher even than
those observed after natural infection with RSV, establishing a first
line of defense against RSV infection in the respiratory tract itself.
These data add to the increasing body of evidence that suggests our
vaccines may provide protection through both systemic and mucosal
immunity, a phenomenon we have also observed in our H1 influenza human
challenge study. RSV is an important public health issue, and we look
forward to building on these results.”
About Respiratory Syncytial Virus (RSV)
RSV is a major cause of acute upper (colds) and lower (pneumonia and
bronchiolitis) respiratory tract infections in infants, young children,
and adults. Each year in the United States, RSV accounts for an
estimated 2.1 million medical visits in children under the age of five,
with many of the children afflicted requiring hospitalization. The CDC
estimates that each year in the United States, more than 177,000 older
adults are hospitalized and 14,000 of them die due to RSV infection. At
the present time there is no effective vaccine to prevent or recommended
therapy to treat RSV infections.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may also be useful for the treatment of chronic viral
infections and cancer. Vaxart’s vaccines are administered using a
convenient room temperature-stable tablet, rather than by injection.
Vaxart believes that tablet vaccines are easier to distribute and
administer than injectable vaccines, and have the potential to
significantly increase vaccination rates. Vaxart’s development programs
include oral tablet vaccines that are designed to protect against
norovirus, seasonal influenza and respiratory syncytial virus (RSV), as
well as a therapeutic vaccine for human papillomavirus (HPV). For more
information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, commercialization agreements and licenses, beliefs
and expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
“believe,” “could,” “potential”, “will” and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to the Vaxart’s ability to develop and
commercialize its product candidates and clinical results and trial
data,. Vaxart may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance on
these forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that Vaxart makes, that Vaxart’s product
candidates may not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or non-U.S. regulatory
authorities, Vaxart’s product candidates may not achieve broad market
acceptance; and the risks described in the “Risk Factors” sections of
Vaxart’s Quarterly Report filed on Form 10-Q for the quarter ended March
31, 2018 and of Vaxart’s other periodic reports filed with the SEC.
Vaxart does not assume any obligation to update any forward-looking
statements, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180627005388/en/
Source: Vaxart, Inc.
Stern Investor Relations
Carl Mauch, 212-362-1200
vaxart@sternir.com